Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VX-984 + PLD in Advanced Solid Tumors
NCT02644278Phase 1Completed
- Sponsor
- EMD Serono
- Start
- Feb 2016
- Primary completion
- Oct 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of VX-984 in solid tumor (advanced stage) and endometrial cancer (EC) (4 arms), sponsored by EMD Serono. Primary endpoints: Treatment Emergent Adverse Events up to 53.1 weeks, Dose Limiting Toxicity and 5 more. Started Feb 2016; status: completed.
02
Drugs
VX-984
03
Conditions
solid tumor (advanced stage)endometrial cancer (EC)
Beyond the preview
Go deeper on NCT02644278.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02644278.